Stimulant medications and attention deficit-hyperactivity disordern [18]

New England Journal of Medicine

Volumn 354, Issue 21, 2006, Pages 2294-2295

  Cohen, Adam L ^a   Jhung, Michael A ^a   Budnitz, Daniel S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; DRUG HYPERSENSITIVITY; DRUG OVERDOSE; DYSPNEA; HEART ARREST; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; LETTER; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; STROKE; SUDDEN DEATH; SYNCOPE; TACHYCARDIA; THORAX PAIN;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG HYPERSENSITIVITY; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; MALE; OVERDOSE; POPULATION SURVEILLANCE; UNITED STATES;

EID: 33646885494     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc060860     Document Type: Letter

References (4)

1. ADHD drug medication guide on potential cardiac risks recommended by committee. 2006. (Accessed May 3, 2006, at http://www.fdaadvisorycommittee.com.)
2. Physicians' desk reference. 60th ed. Montvale, N.J.: Thomson PDR, 2006.
3. Gelperin K, Benoit S, Pamer C. Review of AERS data for marketed safety experience during stimulant therapy: death, sudden death, cardiovascular SAEs (including stroke). Memorandum: Food and Drug Administration Center for Drug Evaluation and Research. April 27, 2004. (Accessed May 3, 2006, at http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4202B1_05_FDA-Tab05.pdf.)
4. Budnitz DS, Pollock DA, Mendelsohn AB, Weidenbach KN, McDonald AK, Annest JL. Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system. Ann Emerg Med 2005;45:197-206.